Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study

被引:1
|
作者
Hyun, Hakjun [1 ]
Choi, Min Joo [4 ,7 ]
Heo, Jung Yeon [5 ]
Seo, Yu Bin [6 ]
Nham, Eliel [1 ]
Yoon, Jin Gu [1 ]
Seong, Hye [1 ]
Noh, Ji Yun [1 ,2 ,3 ]
Cheong, Hee Jin [1 ]
Kim, Woo Joo [1 ,2 ,3 ]
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young [1 ,2 ,3 ]
机构
[1] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul, South Korea
[2] Korea Univ, Asia Pacific Influenza Inst, Coll Med, Seoul, South Korea
[3] Vaccine Innovat Ctr KU Med VIC K, Seoul, South Korea
[4] Catholic Kwandong Univ, Dept Internal Med, Int St Marys Hosp, Coll Med, Incheon, South Korea
[5] Ajou Univ, Dept Infect Dis, Sch Med, Suwon, South Korea
[6] Hallym Univ, Kangnam Sacred Heart Hosp, Dept Internal Med, Div Infect Dis,Coll Med, Seoul, South Korea
[7] Natl Inst Infect Dis, Ctr Vaccine Res, Div Vaccine Clin Res, Cheongju, South Korea
关键词
SARS-CoV-2; COVID-19; Vaccines; Adenovirus Vector; Humoral Immunity; Cellular Immunity; Adverse Events;
D O I
10.3346/jkms.2022.37.e210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. Method: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-. enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. Results: Fifty participants aged >= 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 +/- 3.0 U/mL at 3-4 weeks, 55.7 +/- 2.4 U/mL at 5-8 weeks, and 81.3 +/- 2.5 U/mL at 10-12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS- CoV-2 were 164.6 +/- 4.6 at 3-4 weeks, 313.9 +/- 3.6 at 5-8 weeks, and 124.4 +/- 2.6 at 10-12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0-29.2) at baseline, 60.0 (23.3-178.3) at 5-8 weeks, and 35.0 (13.3-71.7) at 10-12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1-2, and resolved within two days. Conclusion: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5-8 weeks and rather decrease at 10-12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Acute disseminated encephalomyelitis following the COVID-19 vaccine Ad26.COV2.S, a case report
    Stefan Gustavsen
    Mette Maria Nordling
    Arkadiusz Weglewski
    Bulletin of the National Research Centre, 47 (1)
  • [22] Cutaneous leukocytoclastic vasculitis following COVID-19 vaccination with Ad26.COV2.S vaccine: a case report and literature review
    Betetto, Laura Dordevic
    Luzar, Bostjan
    Tkalec, Ziva Pipan
    Ponorac, Svjetlana
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2022, 31 (02): : 83 - 87
  • [23] Comparison of Anti-SARS-CoV-2 IgG Antibody Responses Generated by the Administration of Ad26.COV2.S, AZD1222, BNT162b2, or CoronaVac: Longitudinal Prospective Cohort Study in the Colombian Population, 2021/2022
    Malagon-Rojas, Jeadran
    Mercado-Reyes, Marcela
    Toloza-Perez, Yesith G.
    Galindo, Marisol
    Palma, Ruth M.
    Catama, Jenssy
    Bedoya, Juan F.
    Parra-Barrera, Eliana L.
    Meneses, Ximena
    Barbosa, Juliana
    Tavera-Rodriguez, Pilar
    Bermudez-Forero, Andrea
    Ospina-Martinez, Martha Lucia
    VACCINES, 2022, 10 (10)
  • [24] Guillain-Barre syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy
    Stefanou, Maria Ioanna
    Karachaliou, Eleni
    Chondrogianni, Maria
    Moschovos, Christos
    Bakola, Eleni
    Foska, Aikaterini
    Melanis, Konstantinos
    Andreadou, Elisabeth
    Voumvourakis, Konstantinos
    Papathanasiou, Matilda
    Boutati, Eleni
    Tsivgoulis, Georgios
    NEUROLOGICAL RESEARCH AND PRACTICE, 2022, 4 (01):
  • [25] Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab
    Gudesblatt, Mark
    Zarif, Myassar
    Bumstead, Barbara
    Buhse, Marijean
    Kaczmarek, Olivia
    Li, Hanyue
    Sun, Zhaonan
    Scott, Nicole
    Mendoza, Jason P.
    Avila, Robin L.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2023, 9 (04)
  • [26] Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study
    Jorda, Anselm
    Bergmann, Felix
    Ristl, Robin
    Radner, Helga
    Sieghart, Daniela
    Aletaha, Daniel
    Zeitlinger, Markus
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (09) : 1188 - 1195
  • [27] Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S
    Struyf, Frank
    Hardt, Karin
    Van Rampelbergh, Rian
    Shukarev, Georgi
    Inamdar, Ajinkya
    Ruiz-Guinazu, Javier
    van Paassen, Vitalija
    Anaya-Velarde, Luis
    Diba, Camellia
    Ceuppens, Marc
    Cardenas, Vicky
    Soff, Gerald A.
    Pragalos, Antoinette
    Sadoff, Jerald
    Douoguih, Macaya
    VACCINE, 2023, 41 (37) : 5351 - 5359
  • [28] RCT Abstract-Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults
    Cardenas, Vicky
    Le Gars, Mathieu
    Sadoff, Jerald
    Guinazu, Javier Ruiz
    Vaissiere, Nathalie
    Truyers, Carla
    Scheper, Gert
    Struyf, Frank
    Hendriks, Jenny
    Schuitemaker, Hanneke
    Douoguih, Macaya
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [29] Thrombosis with Thrombocytopenia Syndrome After Administration of AZD1222 or Ad26.COV2.S Vaccine for COVID-19: A Systematic Review
    Waqar, Usama
    Ahmed, Shaheer
    Gardezi, Syed M. H. Ali
    Tahir, Muhammad Sarmad
    ul Abidin, Zain
    Hussain, Ali
    Ali, Natasha
    Mahmood, Syed Faisal
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [30] Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial
    Rezelj, Veronica V.
    Paddenburg, Fred
    Diegbe, Marie Enajite
    Nangosyah, Julius
    Reisinger, Emil C.
    Hu, Weihong
    Truyers, Carla
    Scheper, Gert
    Le Gars, Mathieu
    Hendriks, Jenny
    Struyf, Frank
    Douoguih, Macaya
    Schuitemaker, Hanneke
    Ruiz-Guinazu, Javier
    VACCINES, 2024, 12 (10)